Table 1.

ICIs approved by the US FDA, 2011–21

Drug category	Generic name	Brand name	Approval date	Patent expiry	Manufacturer
CTLA-4 inhibitor	Ipilimumab	Yervoy®	3/25/2011	2023 [41]	Bristol Myers Squibb
PD-1 inhibitor	Pembrolizumab	Keytruda®	9/4/2014	2036 [41]	Merck
PD-1 inhibitor	Nivolumab	Opdivo®	12/22/2014	2027 [41]	Bristol Myers Squibb
PD-L1 inhibitor	Atezolizumab	Tecentriq®	5/18/2016	2028 [41]	Genentech
PD-L1 inhibitor	Avelumab	Bavencio®	3/23/2017	2033 [42]	Merck, Pfizer
PD-L1 inhibitor	Durvalumab	Imfinzi®	5/1/2017	2030 [43]	AstraZeneca
PD-1 inhibitor	Cemiplimab	Libtayo®	9/28/2018	2035 [44]	Regeneron, Sanofi

The above table describes the drug category, generic and brand names, approval date, patent expiry date, and manufacturers of individual ICIs. Approval dates and patent expiry dates in the table are based on US FDA approval and US patents and may be different from those in different countries

CTLA-4 cytotoxic T-lymphocyte-associated protein 4, FDA Food and Drug Administration, ICI immune checkpoint inhibitors, PD-L1 programmed death-ligand 1